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Abstract
Purpose The relationship of allergic diseases, such as asthma, hay fever, and eczema, with cancer is under debate. Obser-
vational studies have reported conflicting findings, but such studies are susceptible to confounding and reverse causation. 
Understanding the potential role of allergy in carcinogenesis may shed new light on the biological mechanisms underpinning 
intrinsic immunity and cancer.
Methods We conducted a Mendelian randomization study, using germline genetic variants as instrumental variables, to 
determine the causal relevance of allergic disease and on two most common malignancies: breast cancer and prostate can-
cer. We used the summary statistics from the largest ever genome-wide association studies conducted on allergic disease 
(ncase = 180,129), asthma (ncase = 14,085), breast (ncase = 122,977), and prostate cancer (ncase = 79,148) and calculated odds 
ratios (ORs) and 95% confidence intervals (CIs) of cancer for allergic disease.
Results We did not observe any evidence to support a causal association between allergic disease and risk of breast can-
cer overall [OR 1.00 (95% CI 0.96–1.04), p = 0.95] or by subtype (estrogen receptor (ER)+ [0.99 (0.95–1.04), p = 0.71], 
ER− [1.05 (0.99–1.10), p = 0.11]). We also did not find any evidence for an association with prostate cancer [1.00 (0.94–1.05), 
p = 0.93] or advanced subtype [0.97 (0.90–1.05), p = 0.46]. Sensitivity analyses did not reveal directional pleiotropy.
Conclusion Our study does not support a causal effect of allergic disease on the risk of breast or prostate cancer. Future 
studies may be conducted to focus on understanding the causal role of allergic disease in cancer prognosis or drug responses 
(e.g., immunotherapy).
Keywords Mendelian randomization · Malignancy · Breast cancer · Prostate cancer · Asthma · Allergy · Causal inference
Introduction
There has been longstanding interest and debate on a pos-
sible relationship of allergic disease (e.g., asthma, hay fever, 
and eczema) with cancer [1, 2]. In general, two distinct and 
contradictory theories have been raised. The immune sur-
veillance hypothesis proposes that the presence of allergies 
reflect an enhanced ability of the immune system to detect 
and destroy malignant cells; thus, having an allergic disorder 
may decrease a person’s cancer risk. In contrast, the antigen 
stimulation hypothesis suggests that chronic stimulation of 
the immune system by allergies may lead to increased levels 
of random pro-oncogenic mutations, repeated tissue inflam-
mation, damage, and repair in favor of cancer onset [3]. 
Understanding the potential role of allergy in carcinogen-
esis is important as it may shed new light on the biological 
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mechanisms underpinning intrinsic immunity and cancer 
and indicate therapeutic implications.
Epidemiologic evidence on associations of allergic dis-
ease with risk of breast and prostate cancer, the two most 
common hormone-driven malignancies among women and 
men, remains inconclusive [4–8]. Methodological concerns 
include small sample size, lack of proper control for con-
founding and bias. Meta-analyses provide a valuable way to 
evaluate the association combining results across studies. 
Vojtechova et al. aggregated data across 16 observational 
studies and found no evidence that allergy or asthma are 
associated with cancers of the breast (ncase = 10,736; relative 
risk (RR) [95% confidence interval (CI)] 1.01 [0.94–1.08] 
for any allergy; 0.93 [0.73–1.19] for asthma) or pros-
tate (ncase = 7,890; 1.01 [0.87–1.17] for any allergy; 0.93 
[0.76–1.15] for asthma) [9]. Similarly, Zhu et al. combined 
data from 20 observational studies and found no association 
of allergy or asthma with prostate cancer (ncase = 19,450; 
0.96 [0.86–1.06] for any allergy; 1.04 [0.92–1.17] for 
asthma) [10]. Such findings, however, could have results 
due to attenuation to the null caused by measurement error 
or masking of a causal effect by confounders. For example, 
individuals with asthma or other allergic diseases might fol-
low a different lifestyle than those without the diseases. They 
are likely to smoke less or refrain from certain foods to avoid 
irritation of diseases; they may pay more attention to envi-
ronmental stimuli that could trigger their symptoms; they 
are less likely to engage with occupations that are exposed 
to high levels of chemical hazards. These confounders could 
possibly alter their risk of cancer onset.
Mendelian randomization (MR) overcomes the limita-
tions of observational approaches by using genetic variants 
(mainly single nucleotide polymorphisms, SNPs) as instru-
mental variables (IVs) to evaluate the potential causal effect 
of an exposure on an outcome [11]. MR is based on the fact 
that: (i) SNPs (genotypes) are randomly assigned at con-
ception, mirroring the randomization process in controlled 
trials and limiting the effect of confounding, and (ii) SNPs 
always precede disease onset, precluding reverse causality. 
Under certain assumptions, namely that the selected IVs are 
associated with the exposure, but not associated with any 
confounder of the exposure–outcome relationship, nor asso-
ciated with the outcome via pathways other than through the 
exposure, an unconfounded estimate of causal effect of an 
exposure can be obtained using the observed IV-exposure 
and IV-outcome associations [12].
The rapidly increasing sample sizes of genome-wide 
association studies (GWAS) and the release of summary-
level data, provides an unprecedented opportunity to conduct 
well-powered MR analyses. In this study, we conducted the 
first and also the largest two-sample MR analysis (with IV-
exposure and IV-outcome associations from two different 
sets of participants) using genetic variants associated with 
a broad allergic disease phenotype including asthma, hay 
fever, or/and eczema as IVs, to appraise the causal relevance 
of allergic disease in cancers.
Methods
Data for IV‑exposure
Two large-scale GWASs on allergic disease have been 
recently published. One was conducted by Ferreira et al. 
using 360,838 individuals of European ancestry which 
identified 136 independent risk variants associated with a 
self-reported broad allergic disease phenotype including 
asthma, hay fever (or allergic rhinitis), and eczema (or atopic 
dermatitis) with p < 310−8. [13] The other was conducted 
by Zhu et al. in 110,361 individuals of European ancestry 
and identified 38 independent risk variants associated with 
a self-reported doctor-diagnosed broad allergic disease 
phenotype including asthma, hay fever (or allergic rhinitis), 
and eczema with p < 510−8. [14] Zhu et al. also identified 
32 asthma-associated SNPs and 33 other allergic diseases-
associated SNPs.
For the current analysis, we retrieved summary data for 
the association between SNPs and allergic disease from 
both GWASs (136 + 38 = 174 SNPs). We filtered the 174 
candidate variants on linkage disequilibrium (r2 < 0.20) and 
restricted to bi-allelic autosomal SNPs, from which, we 
obtained a total of 132 allergic disease-associated SNPs. 
Given the large overlap (> 90%) between participants of the 
two GWASs, and since a majority of final index SNPs (128 
out of 132) were from Ferreira et al., we used effect sizes 
from the larger GWAS (Ferreira et al.) for index SNPs. We 
also included the 32 asthma-specific SNPs and 33 other 
allergic disease-associated SNPs from Zhu et al. in sensitiv-
ity analysis (the analytical procedure is presented in Fig. 1).
Data for IV‑outcome
We retrieved summary data for the association of allergic 
disease or asthma SNPs with breast and prostate cancer from 
the hitherto largest meta-GWAS of these outcomes con-
ducted by the OncoArray network [15]. This is a large-scale 
collaborative effort established to understand the genetic 
architecture and biological mechanisms underlying five 
common cancers (breast, prostate, ovarian, colorectal, and 
lung). Participants of European ancestry were genotyped on 
a custom Illumina array and imputed to the 1000 Genomes 
Project reference panel. For each cancer type, results from 
individual participating GWAS were combined by fixed-
effects inverse-variance weighted meta-analysis, with con-
trol for population stratification within each cohort and 
quality control thresholds of minor allele frequency > 0.01, 
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imputation info score > 0.3, and Hardy–Weinberg equilib-
rium > 1 × 10–12 [16–18].
For breast cancer, 122,977 cases (105,974 controls) 
were involved, of which, 69,501 were estrogen recep-
tor (ER)+ cases and 21,468 were ER− cases; for prostate 
cancer, 79,148 cases (61,106 controls) were involved, of 
which 15,167 were diagnosed with advanced prostate can-
cer (defined as Gleason score 8+ or prostate specific antigen 
[PSA] values > 100 ng/ml at diagnosis; or death from the 
disease or metastatic disease).
Statistical analysis
We conducted a two-sample MR to test for a potential causal 
relationship between allergic disease and risk of breast and 
prostate cancer and their subtypes. We applied a number of 
MR methods including a random-effects inverse-variance 
weighted approach (IVW) [19], a maximum likelihood 
method [20], MR-Egger regression [21], MR-PRESSO [22], 
and a weighted median approach [23].
For each of the k SNPs (IVs), the estimate of genetic 
association with exposure is represented as 𝛽
Xk
 with standard 
error 휎
Xk
 and the estimate of genetic association with out-
come is represented as 𝛽
Yk
 with standard error 휎
Yk
 . The IVW 
estimator can be interpreted as a weighted average of the 
ratio 𝛽Yk
𝛽
Xk
 for each variant, using the reciprocal of an approxi-
mate expression for their asymptotic variance 𝜎
2
Yk
𝛽2
Xk
 . To evalu-
ate potential heterogeneity among causal effects of different 
variants, we employed the Q-test. Complementary to IVW, 
we adopted the maximum likelihood method, which gives 
appropriately sized CIs when there is considerable impreci-
sion in the estimates.
We performed MR-Egger regression and MR-PRESSO 
to both detect and correct for bias due to horizontal pleiot-
ropy, where the average of direct effects of tested genetic 
variants on outcome is non-zero (i.e., violation of exclusion 
Fig. 1  Flow chart of the current Mendelian randomization study. 
For the current analysis, we retrieved summary data for the associa-
tion between SNPs and allergic disease from two GWASs of asthma 
and other allergic diseases (Ferreira et al. and Zhu et al.). We filtered 
these candidate variants on linkage disequilibrium  (r2 < 0.20) and 
restricted to bi-allelic autosomal SNPs, from which, we obtained a 
total of 132 allergic disease-associated SNPs. Given the large over-
lap (> 90%) between the participants of the two GWASs, and since 
a majority of final index SNPs (128 out of 132) were from Ferreira 
et al., we used the effect sizes from the larger GWAS (Ferreira et al.) 
for those index SNPs. We performed a series of sensitivity analysis as 
well as used several MR approaches
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restriction assumption). Under the INstrument Strength 
Independent of Direct Effect (InSIDE) assumption, the 
intercept of MR-Egger regression of 𝛽
Yk
 on 𝛽
Xk
 will be dif-
ferent from zero in the presence of directional pleiotropy, 
and the slope of that regression will be a consistent estimate 
of the causal effect of X on Y.[24] In addition, MR-PRESSO 
implements a global test to evaluate the presence of specific 
outlier variants [22].
Finally, we employed a weighted median method that 
provides consistent estimates even when up to 50% of the 
analyzed genetic variants are invalid IVs.
Sensitivity analyses
We performed a series of sensitivity analyses. In our first 
sensitivity analysis, we restricted the IVs to SNPs at previ-
ous known loci and non-MHC regions. Thus, we used only 
validated results given that both GWASs lacked validations 
and excluded MHC region due to its complicated LD and 
pleiotropy with various diseases. In our second sensitivity 
analysis, we removed SNPs shown to be associated with 
potential confounders of the allergy–cancer association 
according to GWAS catalog (https ://www.ebi.ac.uk/gwas/), 
such as depressive symptom measures, bone mineral density, 
alcohol consumption, markers of infection, and autoimmune 
diseases (Supplementary Table 1). In our third sensitivity 
analysis, we excluded one SNP at-a-time and performed 
IVW on the remaining 131 SNPs to identify potential 
influence of outlying variants on the estimates. Finally, we 
separated asthma from overall allergic disease phenotype to 
understand the cancer-specific effect of asthma.
We estimated the power of our study according to a 
method suggested by Brion et al. [25]. The 132 allergic dis-
ease-associated SNPs collectively explained 1.18% of the 
variance of the phenotype on the observed scale. We fixed 
the type-I error rate at 0.05.
Results
Under the current sample size (Table 1), our study had 
80% power to detect a causal association of a relative 
10.2% change in breast cancer risk and 12.8% for prostate 
cancer; corresponding estimates for ER+ breast cancer, 
ER− breast cancer, and advanced prostate cancer were 
12.2%, 18.5%, and 12.1% relative changes. We also pre-
sented power estimations for a range of proportions of 
phenotype variation explained by the genetic variants (e.g., 
from 1 to 5%).
We did not find any evidence to support a causal role 
of allergic disease in overall (random-effects IVW OR 
[95% CI] 1.00 [0.96–1.04]), ER + (0.99 [0.95–1.04]), or 
ER− (1.05 [0.99–1.10]) breast cancer. Similarly, there 
was little evidence to support a causal role in overall 
prostate cancer (random-effects IVW OR [95% CI] 1.00 
[0.94–1.05]) or its advanced subtype (0.97 [0.90–1.05]) 
(Table 2). Maximum likelihood methods provided similar 
results. However, we detected heterogeneity among the 
estimates of 132 index variants (all pheterogeneity < 0.001 
for overall breast and prostate cancer, and their subtypes), 
indicating the existence of SNP-specific horizontal pleiot-
ropy (scatter plots of effect sizes on exposure vs. outcome 
are shown in Supplementary Fig 1).
Estimates from MR-Egger and weighted median 
approach did not provide any evidence of an effect of 
allergic disease on breast or prostate cancer. We did not 
observe aggregated directional pleiotropy using MR-Egger 
(ppleiotropy for overall breast cancer, ER+ and ER− : 0.93, 
1.00 and 0.85; ppleiotropy for overall prostate cancer and 
its advanced subtype: 0.96 and 0.89. Intercepts and 95% 
CIs are shown in Table 2). We further examined pleiot-
ropy using MR-PRESSO. Although there appeared to 
be a few significant outliers in overall breast cancer and 
Table 1  Number of cancer cases and controls and statistical power in Mendelian randomization study of allergic disease and risk of breast and 
prostate cancer
Minimum detectable odds ratio: assume 80% power, 5% alpha level, and that 1% to 5% of allergic disease heritability is explained by the index 
SNPs used in the current paper
ER estrogen receptor
Cancer type Cases Controls Total Proportion 
of cases
Minimum detectable odds ratio
R2 = 0.01 R2 = 0.02 R2 = 0.03 R2 = 0.04 R2 = 0.05
Breast cancer
 Overall 122,977 105,974 228,951 0.54 0.89/1.12 0.92/1.09 0.94/1.07 0.94/1.06 0.95/1.05
 ER-positive 69,501 95,042 164,543 0.42 0.87/1.15 0.91/1.10 0.92/1.09 0.93/1.07 0.94/1.07
 ER-negative 21,468 100,594 122,062 0.18 0.80/1.25 0.86/1.17 0.88/1.13 0.90/1.11 0.91/1.10
Prostate cancer
 Overall 79,148 61,106 140,254 0.56 0.86/1.16 0.90/1.11 0.92/1.09 0.93/1.08 0.94/1.07
 Advanced 15,167 58,308 73,475 0.21 0.79/1.26 0.85/1.18 0.87/1.15 0.88/1.13 0.90/1.11
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ER+ subset based on global test (none of the outliers were 
associated with known confounders), the outlier-corrected 
results were very similar to those from IVW for both 
breast (OR [95% CI] overall 1.02 [0.98–1.05]; ER+ 1.01 
[0.97–1.05]; ER− 1.05 [0.99–1.10]) and prostate cancer 
(OR [95% CI] overall 1.00 [0.95–1.04]; advanced subtype 
0.96 [0.90–1.04]).
The primary results did not substantially alter in our 
subsequent sensitivity analysis where we excluded SNPs 
from the HLA region (chr6: 25–35 Mb) and restricted to 
only known (and thus validated) SNPs (nSNP = 76; IVW 
OR [95% CI] for overall breast cancer 0.98 [0.93–1.04]; 
ER+ 0.98 [0.92–1.04]; ER− 1.04 [0.98–1.11]; for overall 
prostate cancer 0.99 [0.93–1.06]; advanced subtype 0.99 
[0.90–1.09]) (Table 3). Consistent findings were observed 
when we excluded SNPs associated with potential con-
founders (nSNP = 107; IVW OR [95% CI] for overall breast 
cancer 0.98 [0.94–1.03]; ER+ 0.98 [0.93–1.03]; ER− 0.96 
[0.90–1.02]; for overall prostate cancer 1.01 [0.95–1.08]; 
advanced subtype 0.99 [0.91–1.08]). Similar results were 
observed in the leave-one-out analysis where we iteratively 
removed one SNP each time and performed IVW using the 
remaining 131 SNPs (Supplementary Table 2). We did not 
find any causal effect of doctor-diagnosed asthma or other 
allergic disease on cancers across various MR approaches 
(Table 4).
Table 2  Mendelian 
randomization estimates for the 
causal effect of self-reported 
allergic disease on cancer risk 
using multiple allergy GWAS-
identified variants
p-values < 0.05 are marked in bold
p value for pleiotropy in MR-Egger regression; p value for heterogeneity in inverse-variance weighted anal-
ysis
OR odds ratio, CI confidence intervals
Methods Estimates (OR) 95% CI p value p value for pleiot-
ropy or heteroge-
neity
Overall breast cancer
 Inverse-variance weighted 1.00 (0.96–1.04) 0.95  < 0.001
 Maximum likelihood 1.00 (0.96–1.04) 0.95 NA
 MR-Egger 0.99 (0.89–1.11) 0.92 0.93
 MR-Egger intercept 0.00 (− 0.005 – 0.006)
 Weighted median 1.03 (0.99–1.07) 0.17 NA
ER+ subset
 Inverse-variance weighted 0.99 (0.95–1.04) 0.71  < 0.001
 aximum likelihood 0.99 (0.95–1.04) 0.71 NA
 MR-Egger 0.99 (0.88–1.12) 0.88 1.00
 MR-Egger intercept 0.00 (− 0.006 – 0.006)
 Weighted median 1.00 (0.95–1.05) 0.97 NA
ER− subset
 Inverse-variance weighted 1.05 (0.99–1.10) 0.11  < 0.001
 Maximum likelihood 1.05 (0.99–1.10) 0.11 NA
 MR-Egger 1.03 (0.90–1.19) 0.66 0.85
 MR-Egger intercept 0.00 (− 0.007 – 0.008)
 Weighted median 1.05 (0.97–1.13) 0.23 NA
Overall prostate cancer
 Inverse-variance weighted 1.00 (0.94–1.05) 0.93  < 0.001
 Maximum likelihood 1.00 (0.94–1.06) 0.93 NA
 MR-Egger 1.00 (0.87–1.16) 0.99 0.96
 MR-Egger intercept 0.00 (− 0.014 – 0.014)
 Weighted median 0.95 (0.90–1.01) 0.10 NA
Advanced prostate cancer
 Inverse-variance weighted 0.97 (0.90–1.05) 0.46  < 0.001
 Maximum likelihood 0.97 (0.90–1.05) 0.46 NA
 MR-Egger 0.98 (0.81–1.20) 0.87 0.89
 MR-Egger intercept 0.00 (− 0.014 – 0.014)
 Weighted median 0.95 (0.87–1.05) 0.32 NA
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Discussion
In this study, we used a strong instrumental variable based 
on 132 SNPs and capitalized on summary statistics of 
the largest meta-GWAS conducted for breast and prostate 
cancers in European populations. We aimed to determine 
whether the relationship between allergic disease and risk of 
two cancers was causal by using two-sample MR. In general, 
none of our analyses suggested a causal relationship between 
allergic disease, asthma, and breast or prostate cancer risk.
Our findings are in line with previous reports. Despite 
a few observational studies suggesting a possible associa-
tion of allergic disease or asthma with breast or prostate 
cancer [26-28], such evidence has been scattered, restricted 
by small number of cancer cases (some studies included 
just a couple of hundred cases), and not supported by pro-
spective epidemiological studies. For example, in the meta-
analysis conducted by Vojtechova et al., no association 
was found for any allergy (RR [95% CI] 1.01 [0.94–1.08]) 
or asthma (0.93 [0.73–1.19]) with breast cancer, pooling 
results from both retrospective (ncase = 3,544) and pro-
spective studies (ncase = 7,192). There was no difference 
Table 3  Mendelian randomization estimates for the causal effect of self-reported allergic disease on cancer risk using known allergy-associated 
variants, as well as excluding SNPs associated with potential confounders
p-values < 0.05 are marked in bold
p value for pleiotropy in MR-Egger regression; p value for heterogeneity in inverse-variance weighted analysis
OR odds ratio, CI confidence intervals
Methods Sensitivity Analysis 1: Using previous known allergy-asso-
ciated SNPs, and excluding the HLA region (Nsnp = 76)
Sensitivity Analysis 2: Excluding SNPs associated with 
potential confounders (Nsnp = 107)
Estimates (OR) 95% CI p value p value for pleiot-
ropy or heteroge-
neity
Estimates (OR) 95% CI p value p value for 
pleiotropy or 
heterogeneity
Overall breast cancer
 Inverse-variance 
weighted
0.98 (0.93–1.04) 0.56  < 0.001 0.98 (0.94–1.03) 0.41  < 0.001
 Maximum likelihood 0.98 (0.93–1.04) 0.57 NA 0.98 (0.93–1.03) 0.42 NA
 MR-Egger 1.04 (0.91–1.19) 0.60 0.42 1.08 (0.96–1.23) 0.19 0.08
 Weighted median 1.04 (0.99–1.10) 0.10 NA 0.97 (0.92–1.02) 0.20 NA
ER+ subset
 Inverse-variance 
weighted
0.98 (0.92–1.04) 0.46  < 0.001 0.98 (0.93–1.03) 0.44  < 0.001
 Maximum likelihood 0.98 (0.92–1.04) 0.46 NA 0.98 (0.93–1.03) 0.44 NA
 MR-Egger 1.06 (0.91–1.23) 0.47 0.27 1.11 (0.97–1.27) 0.14 0.05
 Weighted median 1.00 (0.94–1.06) 1.00 NA 0.99 (0.93–1.04) 0.61 NA
ER− subset
 Inverse-variance 
weighted
1.04 (0.98–1.11) 0.23 0.04 0.96 (0.90–1.02) 0.16 0.01
 Maximum likelihood 1.04 (0.98–1.11) 0.23 NA 0.96 (0.90–1.02) 0.16 NA
 MR-Egger 1.07 (0.91–1.27) 0.40 0.67 0.95 (0.81–1.12) 0.54 0.94
 Weighted median 1.05 (0.96–1.14) 0.31 NA 0.93 (0.85–1.01) 0.07 NA
Overall prostate cancer
 Inverse-variance 
weighted
0.99 (0.93–1.06) 0.79  < 0.001 1.01 (0.95–1.08) 0.76  < 0.001
 Maximum likelihood 0.99 (0.92–1.06) 0.79 NA 1.01 (0.94–1.08) 0.76 NA
 MR-Egger 0.93 (0.78–1.11) 0.40 0.43 1.06 (0.88–1.26) 0.55 0.60
 Weighted median 0.94 (0.88–1.00) 0.06 NA 0.96 (0.90–1.02) 0.20 NA
Advanced prostate cancer
 Inverse-variance 
weighted
0.99 (0.90–1.09) 0.86  < 0.001 0.99 (0.91–1.08) 0.81  < 0.001
 Maximum likelihood 0.99 (0.90–1.09) 0.86 NA 0.99 (0.91–1.08) 0.81 NA
 MR-Egger 0.91 (0.71–1.18) 0.49 0.50 1.07 (0.85–1.35) 0.57 0.48
 Weighted median 0.95 (0.85–1.05) 0.31 NA 1.00 (0.90–1.11) 0.98 NA
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in the effect estimates when cohort studies were analyzed 
separately [9]. Similarly, in the meta-analysis conducted by 
Zhu et al., restricting studies to those with a cohort design 
(ncase = 10,769), no association was observed for any allergy 
(1.06 [0.84–1.33]) or asthma (1.02 [0.91–1.15]) with pros-
tate cancer [10]. Consistent with these previous findings, 
we did not observe evidence in support for an association 
between allergy, asthma, and risk of breast or prostate 
cancer.
The null findings of allergy with breast and prostate 
cancer are perhaps not surprising. Carcinogenesis is a 
multi-stage event where different defense mechanisms 
exist in different stages, including but not limited to, 
detoxification of metabolites originated from environ-
mental carcinogens, decomposition to reactive oxygen 
species, DNA repair enzymes, and natural inhibitors of 
proliferating initiated cell [29]. The immune system, which 
acts as maybe the last line of host defense against cancer 
development, can be easily influenced by other existing 
defense mechanisms, leading to either surveillance or tol-
erance. In addition, the relation between allergy and cancer 
has been demonstrated complex and site-specific. While 
firm conclusions cannot be drawn for cancer at many sites, 
strong inverse associations have been reported for pancre-
atic cancer [30], glioma [31], and lymphoma [32], whereas 
positive association has been revealed for lung cancer 
[33] (although most such meta-analysis or pooled studies 
did not analyze prospective studies separately). Several 
shared biological mechanisms have been involved in the 
asthma–lung cancer association, including elevated levels 
of free radicals and reduced levels of antioxidants in the 
respiratory tract, persistent stimulation of cell regeneration 
Table 4  Mendelian randomization estimates for the causal effect of doctor-diagnosed asthma, doctor-diagnosed allergic disease, on cancer risk 
using multiple GWAS-identified variants
p-values < 0.05 are marked in bold
p value for pleiotropy in MR-Egger regression; p value for heterogeneity in inverse-variance weighted analysis
OR odds ratio, CI confidence intervals
Methods Doctor-diagnosed asthma (Zhu et al.) Doctor-diagnosed allergic disease (Zhu et al.)
OR 95% CI p value p value for pleiot-
ropy or heterogeneity
OR 95% CI p value p value for pleiot-
ropy or heteroge-
neity
Overall breast cancer
 Inverse-variance weighted 1.01 (0.97–1.05) 0.54  < 0.001 1.00 (0.94–1.07) 0.97  < 0.001
 Maximum likelihood 1.01 (0.97–1.06) 0.53 NA 1.00 (0.94–1.07) 0.97 NA
 MR-Egger 0.99 (0.86–1.15) 0.93 0.79 0.90 (0.71–1.12) 0.33 0.30
 Weighted median 1.04 (1.00–1.08) 0.04 NA 1.10 (1.00–1.10) 0.03 NA
ER+ subset
 Inverse-variance weighted 1.00 (0.96–1.04) 0.99  < 0.001 1.00 (0.93–1.07) 1.00  < 0.001
 Maximum likelihood 1.00 (0.96–1.05) 0.99 NA 1.00 (0.93–1.07) 1.00 NA
 MR-Egger 0.95 (0.81–1.11) 0.54 0.52 0.90 (0.69–1.12) 0.29 0.27
 Weighted median 0.99 (0.95–1.04) 0.77 NA 1.00 (0.97–1.09) 0.30 NA
ER− subset
 Inverse-variance weighted 1.06 (1.01–1.11) 0.03 0.06 1.10 (0.97–1.14) 0.21  < 0.001
 Maximum likelihood 1.06 (1.01–1.12) 0.03 NA 1.10 (0.97–1.14) 0.20 NA
 MR-Egger 1.15 (0.95–1.38) 0.15 0.39 1.00 (0.72–1.25) 0.69 0.44
 Weighted median 1.07 (1.00–1.14) 0.04 NA 1.10 (1.00–1.18) 0.06 NA
Overall prostate cancer
 Inverse-variance weighted 1.03 (0.96–1.09) 0.43  < 0.001 1.01 (0.94–1.09) 0.75  < 0.001
 Maximum likelihood 1.03 (0.96–1.10) 0.42 NA 1.01 (0.94–1.10) 0.75 NA
 MR-Egger 0.92 (0.73–1.17) 0.50 0.35 1.00 (0.75–1.34) 0.98 0.95
 Weighted median 1.03 (0.98–1.08) 0.27 NA 1.06 (1.00–1.13) 0.05 NA
Advanced prostate cancer
 Inverse-variance weighted 1.02 (0.94–1.10) 0.71  < 0.001 0.99 (0.90–1.09) 0.83  < 0.001
 Maximum likelihood 1.02 (0.94–1.10) 0.70 NA 0.99 (0.90–1.09) 0.83 NA
 MR-Egger 0.84 (0.62–1.13) 0.24 0.18 0.91 (0.63–1.32) 0.62 0.64
 Weighted median 1.00 (0.92–1.09) 0.98 NA 0.99 (0.89–1.09) 0.78 NA
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to repair lung damage, and a heightened sensitivity to car-
cinogens [6]. While the global and individual mechanisms 
involved in other cancer sites might be more complicated 
and less straightforward than in the case of lung cancer, 
current evidence indicates an organ specific immunologi-
cal effect elicited by allergic disease.
Our study has several strengths. We took a series of 
steps to guarantee the validity of estimates. We selected the 
most significant independent SNPs identified by the larg-
est allergic disease GWAS, so all were robustly associated 
with the exposure of interest. These SNPs constitute a strong 
instrument with an F-statistic of 32.6. Secondly, none of the 
instrumental variables used in our analysis were cited by 
the NHGRI-EBI GWAS Catalog as associated with known 
strong confounders of cancer risk, such as BMI, smoking, 
or mammographic density at α = 10–8 level (a full list of 
confounders for asthma–breast cancer association includes 
weight, diet, exercise, alcohol consumption, smoking, stress 
and anxiety, levels of female hormone estrogen; while a full 
list of confounders is less clear for asthma–prostate can-
cer association, it probably includes diet, obesity, smoking, 
and chemical exposure). Nevertheless, some variants were 
indeed associated with autoimmune diseases, psychiatric 
traits and alcohol consumption; however, sensitivity analy-
sis excluding those potentially confounding SNPs provided 
similar results as the primary analysis. Finally, we employed 
sensitivity analyses to control for pleiotropy and obtained 
highly consistent results.
Our current results also provide implications and direc-
tions for future research. While there is no strong evidence 
in support for a putative causal relationship between aller-
gic disease, asthma, and the risk of cancers on breast and 
prostate, it is likely that the presence of allergies, cytokines, 
inflammatory, and immune responses it brings could influ-
ence the prognosis and mortality of cancer. For example, in 
a prospective cohort study of 1,102,247 cancer-free indi-
viduals at baseline, significant inverse associations between 
a history of both asthma and hay fever and overall cancer 
mortality (RR [95%CI] 0.88 [0.83–0.93]) as well as colo-
rectal cancer mortality (0.76 [0.64–0.91]) were found. A 
history of hay fever only was associated with a significantly 
lowered risk of pancreatic cancer mortality, and a history 
of asthma only was associated with a significantly lowered 
risk of leukemia mortality [34]. Another study consisting 
of 475 incident pancreatic cancer cases found allergy to be 
associated with improved prognosis (longer survival among 
those with self-reported allergies than those without: 13.3 
vs. 10.4 months) [35]. Future MR studies may be conducted 
to focus on understanding the causal role of allergic dis-
ease in cancer prognosis or drug responses (e.g., immuno-
therapy), rather than incidence. In addition, allergic disease 
belongs to type-I hypersensitivity, which is characterized by 
an atypical Th2-dominated immune response to innocuous 
environmental agents, leading to a large amount of IgE 
antibody production [36]. Most autoimmune inflammatory 
diseases such as systemic lupus erythematosus, rheumatoid 
arthritis and multiple sclerosis involve different immunologi-
cal mechanisms such as the antigen–antibody complex trig-
gered IgG involved type III hypersensitivity or cell-mediated 
type IV hypersensitivity. It is possible that these immune 
responses may be related to cancer development, and this 
therefore warrants further investigations.
Our study had also several caveats. Despite using the 
largest ever GWAS data on both the exposure and outcome, 
the statistical power in detecting a weak effect is poor—if 
the true causal effect of allergic disease on cancer was less 
than 5%, a magnitude that is probably of limited clinical 
importance—we only had power of 24% for breast cancer 
and 17% for prostate cancer, with our current sample size. 
Although we have involved clinically meaningful disease 
subtypes such as ER+ /− breast cancer and aggressive pros-
tate cancer, we could not examine breast cancer based on 
menopause status (pre- and post-menopause; 85% of breast 
cancer cases in our samples are postmenopausal). In addi-
tion, for two-sample MR to be valid, the two samples have 
to be from the same underlying population, which is not the 
case for our sex-specific cancers. While our outcome data 
are breast cancer in female and prostate cancer in male, we 
could not examine the exposure trait stratified on sex; nei-
ther can we test the association of genetic instruments with 
other effect modifiers such as personal history of allergies, 
physical activity, and hormonal and lifestyle factors, due to 
lack of data. Violation of the exclusion restriction assump-
tion may arise with a binary exposure in MR studies, if it is 
a dichotomization of a continuous risk factor (e.g., allergy 
could be a dichotomization of a continuous spectrum of sub-
clinical problems), then the IVs can influence outcome via 
the continuous risk factor even if the binary exposure stays 
the same. In such cases, calculating a causal estimate can be 
difficult [37]. It may be helpful to test relevant continuous 
variables such as severity of allergy, and immunoglobulin E 
levels when GWAS of such phenotypes become available.
In conclusion, our MR analysis, despite its good overall sta-
tistical power and well-designed analytical protocol, provides 
no evidence in support of a causal relationship between allergic 
disease, asthma, and the risk of breast or prostate cancer.
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